Deans' stroke musings: Nexalin to increase production of in-home, noninvasive deep brain stimulation device

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, April 10, 2024

Nexalin to increase production of in-home, noninvasive deep brain stimulation device

Of course your competent? doctor already is using deep brain stimulation for your recovery? Or don't you have a functioning stroke doctor?

deep brain stimulation (15 posts to July 2015)

Nexalin to increase production of in-home, noninvasive deep brain stimulation device

A Houston-area neurohealth company announced completion of a full production test run, along with usability, feasibility design verification and electrical safety testing for its noninvasive, frequency-based deep brain stimulation device.

According to a release from Nexalin Technology Inc., the company plans to increase manufacture of its Gen-3 HALO Clarity 15 milliamp device ahead of pending clinical trials to be conducted in the United States, with the expectation of producing approximately 500 units in the third quarter of 2024.

Picture of DBS system with human form in outline against a blue background — *Nexalin* *Technologies announced increase in production of its in-home, non-invasive, frequency-based DBS device to address a range of* *neuropsych* *issues.* I *mage* : *Adobe Stock*

Nexalin also stated it will consult with the FDA as part of its presubmission meetings for HALO Clarity, which can be administered at home instead of an external clinical or hospital setting.

The announcement came 5 days after Nexalin revealed the U.S. Patent and Trademark Office issued a patent for the device’s deep brain stimulation technology entitled “Transcranial Alternating Current Dynamic Frequency Stimulation Method for Anxiety, Depression and Insomnia.”

Gen-3 HALO Clarity uses digital breakthrough via electrical waveforms to provide deep and painless brain neural stimulation, which is applied by placing electrodes on the patient’s cranium to offer deep stimulation to regions of the brain associated with mental health conditions, per the release.

“I am thrilled to report that the HALO Clarity passed a series of rigorous tests, validating our manufacturing process and illustrating that our device meets the highest product standards,” Mark White, CEO of Nexalin Technology, stated in the release. “Overall, we are more confident than ever in the HALO Clarity’s potential to revolutionize how we treat mental health disorders in the United States and around the world.”